Record Q2 revenue and EPS growth driven by strong performance in both CooperVision and CooperSurgical, despite Asia-Pac softness and a significant litigation charge. Strategic review of CooperSurgical is advancing, with robust interest and potential for increased share buybacks.Based on The Cooper…Read More
COO: Record revenue, robust cash flow, and strategic review progress despite Asia-Pac headwinds
By TradingView
